Abstract Session 5

Thursday, September 18, 2025

16:00 - 16:50 East Coast USA Time

Location: Room 701

Co-Chair(s)

Nisha Joseph, MD

Associate Professor
Winship Cancer Institute, Emory University
Atlanta, Georgia
Douglas Joshua, Professor (he/him/his)

Emeritus
University of Sydney
SYDNEY, New South Wales, Australia

16:00 - 16:10 East Coast USA Time

(OA-08) Three-Year Follow-Up of FUMANBA-1: a Phase 1b/ 2 Study of Fully Human Anti-BCMA CAR-T Equecabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
Abstract Presenter: Lugui Qiu, MD (he/him/his) – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
16:10 - 16:20 East Coast USA Time

(OA-12) First-in-Human Phase 1 Trial of Trimeric APRIL (TriPRIL) CAR-T Cells in Relapsed or Refractory Multiple Myeloma
Abstract Presenter: Benjamin Puliafito, MD – Massachusetts General Hospital
16:20 - 16:30 East Coast USA Time

(OA-03) Development and Validation of the SCOPE-MM Score: A Pre-Apheresis Risk Model Predicting Response and Toxicity in RRMM Patients Receiving BCMA-Directed CAR-T Therapy
Abstract Presenter: David M. Cordas dos Santos, MD (he/him/his) – Dana-Farber Cancer Institute
16:30 - 16:40 East Coast USA Time

(OA-05) Rapid Peak CAR-T Expansion is Associated with Delayed Neurotoxicity following Ciltacabtagene Autoleucel in Multiple Myeloma
Abstract Presenter: Hitomi Hosoya, MD,PhD – Cedars-Sinai Medical Center
16:40 - 16:50 East Coast USA Time

(OA-71) Concurrent Administration of BCMA and GPRC5D Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma: Results from the Phase I TANDEMM Clinical Trial
Abstract Presenter: Saad Z. Usmani, MD, MBA, FACP, FASCO – Memorial Sloan Kettering Cancer Center